Pharmacophore based virtual screening for natural product database revealed possible inhibitors for SARS-COV-2 main protease

Virology. 2022 May:570:18-28. doi: 10.1016/j.virol.2022.03.003. Epub 2022 Mar 22.

Abstract

The challenge continues globally triggered by the absence of an approved antiviral drug against COVID-19 virus infection necessitating global concerted efforts of scientists. Nature still provides a renewable source for drugs used to solve many health problems. The aim of this work is to provide new candidates from natural origin to overcome COVID-19 pandemic. A virtual screening of the natural compounds database (47,645 compounds) using structure-based pharmacophore model and molecular docking simulations reported eight hits from natural origin against SARS-CoV-2 main proteinase (Mpro) enzyme. The successful candidates were of terpenoidal nature including taxusabietane, Isoadenolin A & C, Xerophilusin B, Excisanin H, Macrocalin B and ponicidin, phytoconstituents isolated from family Lamiaceae and sharing a common ent-kaurane nucleus, were found to be the most successful candidates. This study suggested that the diterpene nucleus has a clear positive contribution which can represent a new opportunity in the development of SARS-CoV-2 main protease inhibitors.

Keywords: COVID-19; Ent-kaurane; Main protease inhibitors; Pharmacophore; Terpenoids.

MeSH terms

  • Antiviral Agents / pharmacology
  • Biological Products* / pharmacology
  • COVID-19 Drug Treatment*
  • Coronavirus 3C Proteases
  • Humans
  • Molecular Docking Simulation
  • Pandemics
  • Peptide Hydrolases
  • Protease Inhibitors / pharmacology
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Biological Products
  • Protease Inhibitors
  • Peptide Hydrolases
  • 3C-like proteinase, SARS-CoV-2
  • Coronavirus 3C Proteases